Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Medical Crossfire®: How Can We Harmonize Pathologic Assessment to Better Drive Immuno-oncology Strategies?

Release Date: April 14, 2020
Expiration Date: April 14, 2021

Activity Overview

In this online Medical Crossfire® program, the expert faculty discuss strategies to use biomarker testing to improve patient care with immunotherapies. PD-L1 expression and microsatellite instability/DNA mismatch repair testing can guide the use of immune checkpoint inhibitors in a broad range of tumor types. However, optimizing biomarker testing and interpreting the results requires close collaboration between oncologists and pathologists to ensure accurate application to the care of patients with cancer. In addition to discussions of how to apply current standards of care, the panel members explore ongoing research to apply biomarker-driven care to predict and diagnose immune-related adverse events. They also discuss emerging biomarkers and future applications for next-generation sequencing and tumor mutation burden. A case-based panel discussion will place these strategies in the context of clinical scenarios.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists and pathologists who treat and manage patients with cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the role, advantages, and limitations of specific biomarker tests from the perspective of expert pathologists evaluating their prognostic and predictive value.
  • Evaluate how pathologists might use emerging biomarkers to anticipate adverse events and which patients are most likely to benefit from treatment with specific checkpoint inhibitors.
  • Identify testing platforms available to pathologists and methodologies for application of these platforms to enable therapeutic decision making.
  • Discuss recent data from trials of checkpoint inhibitors using predictive biomarkers to select appropriate patients for treatment across tumor types.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Lynette M. Sholl, MD
Lynette M. Sholl, MD
Associate Pathologist, Brigham and Women’s Hospital
Associate Professor, Harvard Medical School
Dana-Farber/Harvard Cancer Center
Boston, MA

Disclosures: Consultant: EMD Serono.

Arjun V. Balar, MD
Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Fees for Consultant/Advisory Role: Incyte, Janssen, Pfizer; Fees for Contracted Research (institution), Consultant/Advisory Role, Speaking Engagements: Genentech; Fees for Contracted Research (institution), Consultant/Advisory Role, Speaking Engagements, Steering/Scientific Advisory Committee: Merck; Fees for Consultant/Advisory Role, Contracted Research (institution), Speaking Engagements: AstraZeneca/MedImmune; Fees for Consultant Advisory Role, Contracted Research, Steering Committee Membership: Nektar; Fees for Consultant/Advisory Role, Contracted Research (institution): Seattle Genetics; Fees for contracted research (Institution): Immunomedics.

Balazs Halmos, MD, MS
Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Guardant Health, GlaxoSmithKline, Merck, Mirati, Novartis, Pfizer; Consultant: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Guardant, Merck, Novartis, Pfizer.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By